Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Inclusion Criteria: * Histological or cytologic diagnosis of squamous cell cancer * Clinical diagnosis of squamous cell cancer of the head and neck (non-nasopharynx primary tumors: oral cavity, oropharynx, hypopharynx, larynx and sinonasal) or skin * HNSCC and cSCC cannot be curable by surgery and/or radiation therapy * Measureable disease as per RECIST v1.1, which includes locoregional lesions (not amenable to curative surgery and/or radiation) and distant metastatic lesions * Blood pressure \< 150/90 at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to initiation of treatment * ECOG Performance Status of 0-1 * Adequate renal function as evidenced by calculated creatinine clearance \> 30 ml/min according to the Cockcroft and Gault Formula or by 24 hour urine creatinine clearance * Adequate liver function as determined by (1) Bilirubin \< 1.5 x upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert"s syndrome; (2) ALT and AST \< 3 x ULN (\<5 x ULN if subject has liver mets) * Adequate hematologic function as determined by (1) platelets \> 100,000; (2) Hemoglobin \> 9 gm/dl; (3) absolute neutrophil count \> 1200 * Adequate archival tissue to perform molecular analysis through MSK-IMPACT if MSK-IMPACT has not been performed previously on the patient"s tumor; if MSK-IMACT has not been previously performed and adequate archival tissue is not available, a patient should be agreeab…